Deletions of the long (q) arm of chromosome 5 [del(5q)]occur in patients with myelodysplastic syndromes (MDS) including, but not limited to, those who meet the WHO definition of the 5q− syndrome.
This study builds on previous evidence for lenalidomide-induced selective advantage for TP53-mutant clones. MDS with del(5q) is a specific type of MDS that does not have excess blasts and is ...
Lenalidomide has proven efficacy and safety and has been shown to reduce transfusion requirements and reverse cytogenetic abnormalities in lower-risk myelodysplastic syndromes (MDS). However, ...
The Phase 3 portion of the IMerge Phase 2/3 study is a double-blind, 2:1 randomized, placebo-controlled clinical trial to evaluate imetelstat in patients with IPSS Low or Intermediate-1 risk (lower ...
Dr Haumschild leads a discussion surrounding the latest advancements in treatment algorithms for myelodysplastic syndrome. The discussion centered on diverse treatment strategies for myelodysplastic ...
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced positive top-line results from its IMerge Phase 3 clinical ...
Geron Corporation (NASDAQ:GERN) is one of the best low priced pharma stocks to buy now. Earlier on May 28, Geron Corporation presented new data on RYTELO (imetelstat) at the 2025 American Society of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results